Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?: A case report

RATIONALE: Follicular non-Hodgkin lymphoma (fNHL) is a neoplasm characterized by an indolent course and chemosensitivity, but also by disease recurrence. Bendamustine is often used as frontline treatment or second line. HEADING DIAGNOSIS: fNHL. PATIENT CONCERNS: A 63-year-old Caucasian male with dia...

Descripción completa

Detalles Bibliográficos
Autores principales: Cerchione, Claudio, Nappi, Davide, Musuraca, Gerardo, Lucchesi, Alessandro, Cimmino, Ilaria, Pane, Fabrizio, De Renzo, Amalia, Martinelli, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437798/
https://www.ncbi.nlm.nih.gov/pubmed/32871991
http://dx.doi.org/10.1097/MD.0000000000021440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437798/
https://www.ncbi.nlm.nih.gov/pubmed/32871991
http://dx.doi.org/10.1097/MD.0000000000021440

Ejemplares similares